Before joining Inkef in September 2022, Marcos worked as an investment analyst at Inveready and as a business creation project officer with EIT Health Spain. These positions allowed him to gain valuable experience working with companies in the therapeutics, digital health, and medtech sectors within the European ecosystem. With a background in biochemistry from the University of Barcelona and a master’s degree in business administration, oriented towards the biotech industry, Marcos is well-equipped to understand the challenges and opportunities facing innovative healthcare companies. In his free time, he enjoys cycling, spending time in nature, and exploring new places in the city and abroad.
I’ve always had a soft spot for animals and the mere thought of eating them would make me faint. That’s why some time ago I decided to adopt a plant-based diet and have been exploring sustainable and delicious plant-based recipes since. Eating plant-based helps me stay healthy and reduces my environmental footprint. Also, I heard good things about insect-based diets.
Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of PCSK9, a protein that enables a key step in the control of plasma cholesterol levels.
iOnctura is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. The company is developing a series of assets that can uniquely modulate the tumor micro-environment.
Scenic Biotech BV is a spinout company of the Netherlands Cancer Institute (NKI) and Oxford University, based in Amsterdam, The Netherlands. It is Scenic Biotech’s mission to harness genetic modifiers to combat disease. The company was founded by Prof Thijn Brummelkamp and Prof Sebastian Nijman.
TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. Their technology using small antibodies to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is currently under development for thrombotic thrombocytopenic purpura and Acute Ischemic Stroke.
VarmX is a spin out of Leiden University Medical Center. Its lead program is an innovative antidote for life-threatening bleeding in the ever growing number of patients under Factor Xa anticoagulant treatment. VarmX is also developing new technologies to address risks from new classes of anticoagulants.